Sanofi SA is restructuring its portfolio to focus on developing new specialty care medicines including those for rare blood disorders, while maintaining a commitment to vaccines. The France-based multinational gave the R&D update with the release of its 2018 financial results which showed a decline in both group sales and net income.
Group sales were €34.5 billion, down by 1.7% while net income was €4.3 billion, down by 48.8%, in accordance with international financial reporting standards.